BACKGROUND Predictors of response of chronic hepatitis B (CHB) to lamivudine therapy need better definition. Whether hepatitis B virus (HBV) genotypes could serve as such a predictor has not been well studied. AIM To study the association of HBV genotypes with the outcome of lamivudine treatment in patients with CHB. METHODS Seventy-six patients with CHB (45 HBeAg +ve) received lamivudine 1...

INTRODUCTION Treatment of genotype 1 chronic hepatitis C in elderly patients has been associated with low rates of a sustained virological response (SVR), but the reasons are unclear. OBJECTIVE To determine the SVR rate in patients ≥ 60 years with genotype 1 chronic hepatitis C treated with Peg-IFN and ribavirin, and to identify risk factors related to treatment response in this specific grou...

results overall, 3 (15%) subjects achieved svr, 10 cases (50%) relapsed after treatment cessation and 7 (35%) patients did not clear hdv during the treatment. conclusions hdv coinfection with hbv had very low response rate to high doses and long durations of ifn α-2b therapy. objectives we aimed to determine the efficacy of ifn α-2b therapy in patients with hbv/hdv coinfection. patients and met...

BACKGROUND Inflammatory gene expression in peripheral blood mononuclear cells (PBMCs) is altered in chronic Hepatitis C Virus (HCV) infection. Duration of changes after pegylated interferon- (peg-IFN-) based HCV treatment is unclear. METHODS PBMC mRNA expression of 184 inflammatory response genes was analyzed (nCounter GX Human Inflammation Kit, Nanostring) from peg-IFN treatment nonresponder...

BACKGROUND A substantial proportion of hepatitis C virus (HCV)-1b infected patients do not response to pegylated interferon-α plus ribavirin (PegIFNα/RBV) combination therapy that was partially associated with mutations in the non-structural 5A (NS5A) protein. OBJECTIVES Analysis of NS5A polymorphisms in HCV genotype 1b pre-treatment serum samples from Estonian patients and their effect on th...

BACKGROUND A recent genome-wide association study (GWAS) on patients with chronic hepatitis C (CHC) treated with peginterferon and ribavirin (pegIFN-α/RBV) identified a single nucleotide polymorphism (SNP) on chromosome 19 (rs12979860) which was strongly associated with a sustained virological response (SVR). The aim of this study was twofold: to study the relationship between IL28B rs12979860 ...

AIM OF THE STUDY To assess predictors of sustained virological response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 3 treated with standard therapy. MATERIAL AND METHODS We retrospectively investigated data of 116 consecutive treatment-naïve patients chronically infected with HCV genotype 3, treated with pegylated interferon alpha (PegIFNα) and ribavirin (RBV) for 24 weeks...

Objectives: The aim of the study was to evaluate sustained virological response (SVR) after treatment and factors that influence SVR among patients treated for chronic hepatitis C (CHC). Materials and methods: The study was conducted in patients with CHC between April 2007 and March 2011, who had achieved SVR following treatment. They were treated with PEG IFN-α and ribavirin. Patients, whose e...

Few studies have been conducted in the Eastern Mediterranean region on chronic hepatitis C virus (HCV) infection with reference to genotypes. We investigated the response to standard combination therapy (pegylated interferon/ribavirin) of different genotypes of HCV in Kuwaiti patients and factors that could be associated with sustained virological response (SVR). The records of all Kuwaiti pati...

BACKGROUND Treatment of Chronic Hepatitis C is now well established with conventional interferon or pegylated interferon in combination with ribavirin. Peginterferon Alfa and Ribavirin for 6 to 12 months is currently approved initial therapy, which is expensive. Response of our patients to standard Interferon-alpha-2b and ribavirin for 24 weeks have been studied. The objective of this study was...